{
    "clinical_study": {
        "@rank": "16832", 
        "brief_summary": {
            "textblock": "PRIMARY: To study the safety and tolerance of delavirdine mesylate ( U-90152 ) monotherapy.\n      To compare the anti-HIV activity of three blood concentration levels of this agent with\n      nucleoside analog monotherapy, either zidovudine ( AZT ) or didanosine ( ddI ), based on the\n      reduction of HIV viral burden.\n\n      SECONDARY: To use pharmacokinetic parameters to assess the relationship between daily drug\n      exposure and antiviral activity and toxicity of the U-90152, AZT, and ddI monotherapy. To\n      assess anti-HIV activity using other disease markers.\n\n      Data suggest that bisheteroarylpiperazines (BHAPs) such as delavirdine mesylate are potent\n      and safe anti-HIV agents and may have different biological behavior than other currently\n      available non-nucleoside RT inhibitors."
        }, 
        "brief_title": "Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)", 
        "completion_date": {
            "#text": "January 1996", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Data suggest that bisheteroarylpiperazines (BHAPs) such as delavirdine mesylate are potent\n      and safe anti-HIV agents and may have different biological behavior than other currently\n      available non-nucleoside RT inhibitors.\n\n      Patients are randomized to receive U-90152 at one of three doses (treatment arms I through\n      III) or either AZT or ddI (treatment arm IV). Patients on arm IV who are AZT-naive receive\n      AZT; those who are AZT-experienced receive ddI. Treatment continues for 24 weeks.\n\n      PER 12/22/94 AMENDMENT: All patients receiving U-90152 have the same starting dose, to\n      attain one of three target trough levels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  PCP prophylaxis.\n\n          -  Topical antifungal agents, clotrimazole troches, nystatin oral suspension, topical\n             ketoconazole, and oral fluconazole.\n\n          -  Acyclovir (<= 1000 mg/day) as maintenance therapy for herpes simplex virus.\n\n          -  Recombinant erythropoietin and G-CSF.\n\n          -  Antibiotics for bacterial infections, unless specifically excluded.\n\n          -  Symptomatic treatment such as antipyretics, analgesics, nonsteroidal\n             anti-inflammatory agents, and antiemetics.\n\n          -  Antacids.\n\n        Patients must have:\n\n          -  HIV-1 infection.\n\n          -  CD4 count 200 - 500 cells/mm3.\n\n          -  Either no prior antiretroviral therapy or discontinued AZT monotherapy 3 or more\n             weeks prior to study entry.\n\n        NOTE:\n\n          -  Half of patients should be antiretroviral naive.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior AZT.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Malignancy other than minimal Kaposi's sarcoma.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Rifabutin.\n\n          -  Rifampin.\n\n          -  Terfenadine.\n\n          -  Astemizole.\n\n          -  Loratadine.\n\n          -  Trifluoperazine.\n\n          -  Piperazine citrate.\n\n          -  Any acute or chronic therapy for CMV, MAC, toxoplasmosis, or disseminated fungal\n             infection.\n\n          -  Non-study antiretroviral therapies, interferons, biologic response modifiers, and HIV\n             vaccines.\n\n          -  Systemic corticosteroids for more than 21 consecutive days.\n\n          -  Foscarnet.\n\n          -  Systemic cytotoxic chemotherapy for a malignancy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of pancreatitis (in patients who received prior AZT).\n\n          -  History of grade 2 or worse peripheral neuropathy (in patients who received prior\n             AZT).\n\n          -  History of hypersensitivity to BHAP compounds (e.g., trifluoperazine - Stelazine,\n             piperazine citrate - Antepar).\n\n        Prior Medication:\n\n        Excluded within 30 days prior to study entry:\n\n          -  Any investigational medication.\n\n          -  Interferon.\n\n          -  Interleukin.\n\n          -  Rifabutin.\n\n          -  Rifampin.\n\n          -  Terfenadine.\n\n          -  Astemizole.\n\n          -  Loratadine.\n\n          -  Trifluoperazine.\n\n          -  Piperazine citrate.\n\n        Excluded at any time:\n\n          -  Prior ddI, ddC, d4T, or 3TC.\n\n          -  Prior foscarnet.\n\n          -  Prior BHAP compound or other non-nucleoside RT inhibitor.\n\n        Active substance abuse interfering with compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000810", 
            "org_study_id": "ACTG 260", 
            "secondary_id": "11237"
        }, 
        "intervention": [
            {
                "intervention_name": "Delavirdine mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Zidovudine", 
                "Delavirdine"
            ]
        }, 
        "keyword": [
            "Didanosine", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents", 
            "Zidovudine"
        ], 
        "lastchanged_date": "April 2, 2012", 
        "link": [
            {
                "description": "Click here for more information about Zidovudine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
            }, 
            {
                "description": "Click here for more information about Didanosine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=16"
            }, 
            {
                "description": "Click here for more information about Delavirdine mesylate", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=166"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "943055107"
                    }, 
                    "name": "Stanford CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "University of Colorado Hospital CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20059"
                    }, 
                    "name": "Howard University Hosp., Div. of Infectious Diseases, ACTU"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "331361013"
                    }, 
                    "name": "Univ. of Miami AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Indiana Univ. School of Medicine, Infectious Disease Research Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "SUNY - Buffalo, Erie County Medical Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ. of Rochester ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Unc Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "The Ohio State Univ. AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)", 
        "overall_official": [
            {
                "last_name": "Para M", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Fischl M", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Dereuddre-Bosquet N, Clayette P, Martin M, Fretier P, Jaccard P, Benveniste O, Lebeaut A, Dormont D. IL-10 and HIV-1 infection of human primary monocyte/macrophages. Int Conf AIDS. 1996 Jul 7-12;11(2):75 (abstract no WeA3107)"
            }, 
            {
                "citation": "Para M, Weinstock M. Retrospective analysis of protease inhibitor efficacy among patients failing a delavirdine regimen. Int Conf AIDS. 1998;12:59 (abstract no 12236)"
            }, 
            {
                "citation": "Morse G, Para M, Fischl M, Freimuth W. Concentration-targeted (CT) Delavirdine therapy in 82 patients in ACTG 260. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:118"
            }, 
            {
                "citation": "Para M, Morse G, Fischl M. Plasma protein binding of delavirdine in HIV-infected patients in ACTG 260. Int Conf AIDS. 1996 Jul 7-12;11(2):78 (abstract no WeB3131)"
            }, 
            {
                "citation": "Demeter L, Shafer R, Para M, Morse G, Freimuth W, Merigan T, Reichman R. Delavirdine (DLV) susceptibility of HIV-1 isolates obtained from patients (pts) receiving DLV monotherapy (ACTG 260). Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:113"
            }, 
            {
                "citation": "Para MF, Fischl M, Meehan P, Morse G, Wood K, Shafer R, Freimuth W, Demeter L, Holden-Wiltse J, Nevin T. ACTG 260: Randomized phase I/II concentration-controlled trial of the anti-HIV activity of delavirdine. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:163"
            }, 
            {
                "PMID": "10681363", 
                "citation": "Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother. 2000 Mar;44(3):794-7."
            }, 
            {
                "PMID": "10348755", 
                "citation": "Para MF, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter LM, Wood K, Nevin T, Virani-Ketter N, Freimuth WW. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrob Agents Chemother. 1999 Jun;43(6):1373-8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000810"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Howard University Hosp., Div. of Infectious Diseases, ACTU": "38.895 -77.036", 
        "Indiana Univ. School of Medicine, Infectious Disease Research Clinic": "39.769 -86.158", 
        "Northwestern University CRS": "41.878 -87.63", 
        "SUNY - Buffalo, Erie County Medical Ctr.": "42.886 -78.878", 
        "Stanford CRS": "37.429 -122.169", 
        "The Ohio State Univ. AIDS CRS": "39.961 -82.999", 
        "Unc Aids Crs": "35.913 -79.056", 
        "Univ. of Miami AIDS CRS": "25.789 -80.226", 
        "Univ. of Rochester ACTG CRS": "43.161 -77.611", 
        "University of Colorado Hospital CRS": "39.729 -104.832"
    }
}